This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

aaiPharma Falls on Filing Delay





aaiPharma (AAII) shares fell before the open Monday after the troubled biotech company decided to delay the filing of its annual report because of what it recently described as "unusual sales."

The company mentioned the possibility earlier this month, when it announced the discovery of unusual sales involving two of its drugs and said it might have to make an adjustment in 2003 financial results. That triggered an investigation by a panel of independent directors and the withdrawal of 2004 earnings guidance.

Following the March 1 announcement, the company's shares plummeted as analysts downgraded the stock and even dropped coverage.

In a statement Monday, the company said "the independent inquiry is ongoing and neither the company nor the board will be commenting further at this time." aaiPharma said the filing date for its 2003 10-K form will be extended to March 30 from March 15.

The filing delay involving the sales issue is the latest blow to the company. In February, aaiPharma announced it had set aside a $15.9 million reserve against revenue in the fourth quarter of 2003 to account for products that are returned. Shortly after that, aaiPharma said its chief operating officer was leaving to become president of a startup drug company.

Shares fell 30 cents, or 3.1%, to $9.11 in premarket trading. Shares were at a 52-week high of $31.85 in early January.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AAPL $132.03 1.90%
FB $80.55 1.50%
GOOG $539.80 1.40%
TSLA $247.43 -0.01%
YHOO $43.39 1.30%

Markets

DOW 18,162.99 +121.45 0.67%
S&P 500 2,123.48 +19.28 0.92%
NASDAQ 5,106.5930 +73.8420 1.47%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs